b'E x e c u t i v eL e a d e r s h i p Te a mJeffrey Edward Miller, Ph.D.Dr. Bradley Patay, M.D. Founder, Chief Scientific Officer, & Chief Executive Officer Chief Medical OfficerDr. Miller is a scientist, inventor, and entrepreneur focused on Improving Lives with Precision DiagnosticscouplingDr. Patay is dedicated to improving health by integrating genomic knowledge into medical care. He has authored numerous drug trials and therapeutic treatment regimens with optimized clinically-actionable diagnostic methods in order to selectarticles in this field, presented at multiple conferences and has been featured in Bloomberg Business Week. He has been head the correct patients and then monitor and track their response throughout the course of their disease. He received hisof the internal medicine section at Scripps Torrey Pines, worked as an Assistant Professor at STSI, and has been a founding undergraduate degree in Biochemistry from UCLA and a combined Ph.D. in Biochemistry & Molecular Biology from UCSB.member of the Board, and Vice President of the College of Genomic Medicine, which was established in 2010 to educate Prior to starting Invivoscribe, Dr. Miller had more than twenty years of combined experience in protein biochemistry, cellularphysicians and other health care professionals about genomic medicine. His diverse clinical experience prior to joining Scripps and molecular immunology, cardiac physiology, virology, and molecular biology, experience he had developed working Clinic in 2005 includes four years as an internist and pediatrician at Neighborhood Healthcare, a private, nonprofit community in laboratories at the Medical School, Department of Chemistry, Molecular Biology Institute at UCLA, while earning his Ph.D.healthcare practice, and at Palomar Hospital. At these institutions, Brad cared for a wide range of patients, from neonates at UCSB, and as a postdoctoral scientist at Applied Molecular Evolution. He also spent several years at Quest Diagnosticsto the elderly, in both intensive care and the general wards. Through his service on several committees, he helped improve Jeffrey Edward MillerNichols Institute, setting up the molecular oncology laboratory and developing and launching PCR-based molecular assaysDr. Bradley Patay health care institutions systems.for infectious disease and hematopathology.Meghna Bhatnagar, MBAPaul McMullin, MIM, MBA Chief Financial Officer Head of Global Sales & MarketingMeghna Bhatnagar joined Invivoscribe in 2010 as Chief Financial Officer. In this role she is responsible for leading thePaul McMullin joined Invivoscribe in 2018 as the Head of Global Sales & Marketing. In this role, he leads Invivoscribes Invivoscribe global finance organization, along with human resources and information technology. Since her arrival, worldwide Sales and Marketing efforts with focus on both Diagnostic and Companion Diagnostics (CDx) Products.Ms. Bhatnagar has played an integral role in directing all aspects of company strategy, planning and operations. These Products are sold in over 100 Countries via a Direct Sales Organization as well as Exclusive Distributors. Mr. McMullin Ms. Bhatnagar has over 20 years of experience building and leading finance and IT teams in global companies. Prior tohas over 35 years of experience working in the Medical Diagnostics Business. Most of that time has been in the molecularjoining IVS, she served as COO of Radiant Technologies, a technology company focused on providing business managementand biotechnology fields. His experience includes numerous positions in Sales and Marketing, establishing Direct Sales, solutions to small and medium sized companies where she was responsible for leadership and development of an entireService and Support companies in Europe and Australia, and managing Distributor Sales in over 55 countries worldwide.project delivery team with full P&L responsibility. She played a key role in guiding overall strategy of the company and at theHe has directly managed employees in Japan, China and most major EU countries.Meghna Bhatnagar same time provided leadership for operational improvements. Paul McMullinTony LialinJason GerholdChief Commercial Officer Global Director, Regulatory Affairs/Quality AssuranceTony Lialin joined Invivoscribe in 2021 as Chief Commercial Officer. In this role he is responsible for leading the globalJason Gerhold joined Invivoscribe in 2012 and serves as the Global Director of Regulatory, Quality, and Clinical Affairs focusing commercial organization. Mr. Lialin has more than two decades of experience in growing companies in the life scienceson developing high quality diagnostics that meet both international pathology needs and support pharma partners drug industry having held positions in clinical diagnostic, bioinformatics software, instrumentation and reagent companies. development programs. He directly manages employees in the US, Japan, and China, and is responsible for worldwide He has successfully scaled commercial operations at three start-ups resulting in those companies being purchased by largecompliance to relevant laws, regulations, and standards. Mr. Gerhold has over 20 years of experience in the biotech industry public companies. Mr. Lialin comes to IVS from Loop Genomics, an NGS long-read sequencing company where he startedwith biologic therapeutics and diagnostics, including process development, regulatory, quality, and clinical roles. Mr. Gerhold their global commercial operations growing their business to several million dollars in revenue per year in just three years.has worked in small, medium and large companies; successfully registering IVD and CDx products in several international From 2014 through June 2018, Mr. Lialin managed $400M in portfolio business at Illumina working closely with customers markets, developing, improving, and maintaining quality management systems while serving as the management in the DTC, Oncology and Postnatal testing spaces. He also served as a director at Agilent Technologies, where he managedrepresentative to regulatory authorities, and leading clinical teams managing international registrational studies. He is known the emerging market, field application scientist, and technical support and field service engineering teams.As a six-sigmafor building strong rapport with regulators and working well with research and pharma teams resulting in highly successful Tony Lialin green belt he values process, service as a differentiator and both internal and external customers. Mr. Lialin earned Jason Gerhold partnerships. He has completed trainings and/or accreditations for ISO 13485 Lead Auditor, Six Sigma Greenbelt, Clinical Trials a BA in Molecular Cellular and Developmental Biology from the University of California at Santa Cruz. Administration, Project Management, and CTD writing.8Invivoscribe 2021|9'